Rapamycin improves healthspan but not inflammaging in nfκb1−/− mice

Increased activation of the major pro‐inflammatory NF‐κB pathway leads to numerous age‐related diseases, including chronic liver disease (CLD). Rapamycin, an inhibitor of mTOR, extends lifespan and healthspan, potentially via suppression of inflammaging, a process which is partially dependent on NF‐...

Full description

Saved in:

Bibliographic Details
Published in:	Aging cell 2019-02, Vol.18 (1), p.e12882-n/a
Main Authors:	Correia‐Melo, Clara, Birch, Jodie, Fielder, Edward, Rahmatika, Dina, Taylor, Jennifer, Chapman, James, Lagnado, Anthony, Carroll, Bernadette M., Miwa, Satomi, Richardson, Gavin, Jurk, Diana, Oakley, Fiona, Mann, Jelena, Mann, Derek A., Korolchuk, Viktor I., Passos, João F.
Format:	Article
Language:	English
Subjects:	Age Aging Animals Biomarkers - metabolism Chronic illnesses inflammaging Inflammation Inflammation - pathology Life span Liver diseases Longevity - drug effects Longevity - physiology Mice, Inbred C57BL Mice, Knockout Mitochondria - drug effects Mitochondria - metabolism mTOR NF-kappa B - deficiency NF-κB protein Original Paper Original Papers Phenotypes Rapamycin SASP Senescence Signal transduction Sirolimus - pharmacology TOR protein
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!